Disease · MONDO_0005028
Comparisons in its trials24
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 24
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pembrolizumab vs Chemotherapy: Number of Participants Experiencing an Adverse Event (AE) | 301 of 314 | 288 of 296 | 610 | NCT02564263 | Trial comparisons |
| Pembrolizumab vs Chemotherapy: Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE) | 40 of 314 | 42 of 296 | 610 | NCT02564263 | Trial comparisons |
| CapeOx Plus Lapatinib vs CapeOx Plus Placebo: Percentage of Participants With Clinical Benefit (CB) | 199 of 249 | 188 of 238 | 487 | NCT00680901 | Trial comparisons |
| CapeOx Plus Lapatinib vs CapeOx Plus Placebo: Percentage of Participants With a Confirmed Complete Response (CR) or a Partial Response (PR) | 131 of 249 | 94 of 238 | 487 | NCT00680901 | Trial comparisons |
| Chemoradiation and Trastuzumab (Arm 1) vs Chemoradiation (Arm 2): Number of Participants With Any Cardiac Adverse Events Regardless of Attribution | 30 of 95 | 24 of 96 | 191 | NCT01196390 | Trial comparisons |
| Chemoradiation and Trastuzumab vs Chemoradiation: deaths from any cause | 53 of 95 | 55 of 96 | 191 | NCT01196390 | Trial comparisons |
| Chemoradiation and Trastuzumab vs Chemoradiation: serious adverse events | 51 of 95 | 34 of 96 | 191 | NCT01196390 | Trial comparisons |
| Ramucirumab and mFOLFOX6 vs Placebo and mFOLFOX6: serious adverse events | 48 of 82 | 32 of 80 | 162 | NCT01246960 | Trial comparisons |
| Ramucirumab and mFOLFOX6 vs Placebo and mFOLFOX6: Number of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies | 0 of 81 | 1 of 77 | 158 | NCT01246960 | Trial comparisons |
| PDR001+LAG525 On-treatment Period vs PDR001+LAG525 Extended Safety Follow-up Period: deaths from any cause | 9 of 76 | 18 of 76 | 152 | NCT03365791 | Trial comparisons |
| PDR001+LAG525 On-treatment Period vs PDR001+LAG525 Extended Safety Follow-up Period: serious adverse events | 31 of 76 | 4 of 76 | 152 | NCT03365791 | Trial comparisons |
| Pembrolizumab 200 mg First Course vs Pembrolizumab 200 mg Second Course: deaths from any cause | 116 of 121 | 0 of 1 | 122 | NCT02559687 | Trial comparisons |
| Pembrolizumab 200 mg First Course vs Pembrolizumab 200 mg Second Course: serious adverse events | 47 of 121 | 0 of 1 | 122 | NCT02559687 | Trial comparisons |
| Pembrolizumab vs Chemotherapy: Number of Participants Experiencing an Adverse Event (AE) | 62 of 62 | 56 of 59 | 121 | NCT03933449 | Trial comparisons |
| Pembrolizumab vs Chemotherapy: Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE) | 10 of 62 | 9 of 59 | 121 | NCT03933449 | Trial comparisons |
| mFOLFOX6 + Ziv-aflibercept vs mFOLFOX6 + Placebo: deaths from any cause | 2 of 43 | 0 of 21 | 64 | NCT01747551 | Trial comparisons |
| mFOLFOX6 + Ziv-aflibercept vs mFOLFOX6 + Placebo: serious adverse events | 34 of 43 | 9 of 21 | 64 | NCT01747551 | Trial comparisons |
| Arm I (DOC, 5FU/O/RT, Surgery) vs Arm II (5FU/O/RT, Surgery): serious adverse events | 7 of 34 | 7 of 28 | 62 | NCT00938470 | Trial comparisons |
| Cohort 1 vs Cohort 2: deaths from any cause | 7 of 20 | 9 of 22 | 42 | NCT02998268 | Trial comparisons |
| Cohort 1 vs Cohort 2: serious adverse events | 8 of 20 | 13 of 22 | 42 | NCT02998268 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005028/comparisons